REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

14/07/2021 15:35

RNS Number : 2674F
  
GlaxoSmithKline PLC
  
14 July 2021
  
 

GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms E Walmsley




b)


Position/status


Chief Executive Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


927


 




 


£14.2600


745


 




 


£14.2600


620


 




 


 


 


 




d)


Aggregated information
 


2,292




 
Aggregated volume Price


 
£14.2600




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Dr H Barron




b)


Position/status


Chief Scientific Officer and President, R&D




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 8 July 2021 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$39.9700


540


 




 


$39.9700


424


 




 


$39.9700


321


 




 


 


 


 




d)


Aggregated information
 


1,285




 
Aggregated volume Price


 
$39.9700




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor     
 




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


243


 




 


£14.2600


235


 




 


£14.2600


136


 




 


 


 


 




d)


Aggregated information
 


614




 
Aggregated volume Price


 
£14.2600




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Conrad




b)


Position/status


SVP Human Resources




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


97


 




 


£14.2600


90


 




 


 


 


 




d)


Aggregated information
 


187




 
Aggregated volume Price


 
£14.2600




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


Senior Vice President and General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


138


 




 


£14.2600


108


 




 


 


 


 




d)


Aggregated information
 


246




 
Aggregated volume Price


 
£14.2600




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


Senior Vice President and General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 8 July 2021 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$39.9700


46


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


101


 




 


£14.2600


73


 




 


£14.2600


54


 




 


 


 


 




d)


Aggregated information
 


228




 
Aggregated volume Price


 
£14.2600




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms S Jackson




b)


Position/status


SVP, Global Communications & CEO Office




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


58


 




 


£14.2600


54


 




 


 


 


 




d)


Aggregated information
 


112




 
Aggregated volume Price


 
£14.2600




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr I Mackay




b)


Position/status


Chief Financial Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


503


 




 


£14.2600


430


 




 


 


 


 




d)


Aggregated information
 


933




 
Aggregated volume Price


 
£14.2600




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr B McNamara




b)


Position/status


CEO, GSK Consumer Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 8 July 2021 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$39.9700


91


 




 


$39.9700


78


 




 


$39.9700


98


 




 


 


 


 




 


 


 


 




d)


Aggregated information
 


267




 
Aggregated volume Price


 
$39.9700




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


258


 




 


£14.2600


225


 




 


£14.2600


168


 




 


 


 


 




d)


Aggregated information
 


651




 
Aggregated volume Price


 
£14.2600




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


229


 




 


£14.2600


165


 




 


£14.2600


132


 




 


 


 


 




d)


Aggregated information
 


526




 
Aggregated volume Price


 
£14.2600




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharmaceuticals Supply Chain




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


83


 




 


£14.2600


117


 




 


£14.2600


99


 




 


 


 


 




d)


Aggregated information
 


299




 
Aggregated volume Price


 
£14.2600




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms K Terrell




b)


Position/status


Chief Digital & Technology Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 8 July 2021 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$39.9700


115


 




 


$39.9700


79


 




 


$39.9700


62


 




 


 


 


 




d)


Aggregated information
 


256




 
Aggregated volume Price


 
$39.9700




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


134


 




 


£14.2600


95


 




 


£14.2600


77


 




 


 


 


 




d)


Aggregated information
 
 


306




Aggregated volume Price


£14.2600




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Waterhouse




b)


Position/status


Chief Executive Officer of ViiV Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.2600


158


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-07-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHZZLFFFDLXBBL